Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Thyroid Neoplasms 1Neoplasm Metastasis 1Differentiated Thyroid Carcinoma 1

Interventions

Specimen Handling 40Biopsy 33Magnetic Resonance Spectroscopy 26pembrolizumab 21Nivolumab 11Paclitaxel 10trastuzumab deruxtecan 9Carboplatin 9Irinotecan 8Gemcitabine 8Radiosurgery 7Leucovorin 7Fluorouracil 7Bevacizumab 7palbociclib 6X-Rays 6Pemetrexed 6Ipilimumab 6Fulvestrant 6Cetuximab 6Capecitabine 6Taxes 5Oxaliplatin 5Letrozole 5Cisplatin 5130-nm albumin-bound paclitaxel 5durvalumab 4abemaciclib 4Trastuzumab 4CTLA-4 Antigen 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × Iodine-124 × 30 days × Clear all
NCT03841617 2026-06-05

The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
30 enrolled
Head & Neck

Neoplasm Metastasis, Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡